BSE Live
Apr 20, 16:01Prev. Close
1403.15
Open Price
1403.15
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 20, 15:55Prev. Close
1402.10
Open Price
1404.50
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1418.60 (24)
| Profit & Loss account of Dr Lal PathLabs (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 2,461.22 | 2,226.50 | 2,016.64 | 2,087.28 | 1,581.18 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 2,461.22 | 2,226.50 | 2,016.64 | 2,087.28 | 1,581.18 | |
| Total Operating Revenues | 2,461.40 | 2,226.64 | 2,016.88 | 2,087.41 | 1,581.27 | |
| Other Income | 93.43 | 69.17 | 41.72 | 52.55 | 51.33 | |
| Total Revenue | 2,554.83 | 2,295.81 | 2,058.60 | 2,139.95 | 1,632.60 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Purchase Of Stock-In Trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating And Direct Expenses | 481.46 | 451.42 | 447.15 | 502.25 | 397.26 | |
| Changes In Inventories Of FGWIP And Stock In Trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Employee Benefit Expenses | 482.36 | 424.57 | 376.52 | 364.94 | 273.70 | |
| Finance Costs | 22.31 | 29.36 | 37.53 | 30.18 | 16.00 | |
| Depreciation And Amortisation Expenses | 141.92 | 143.60 | 150.19 | 108.11 | 77.20 | |
| Other Expenses | 801.98 | 741.41 | 703.37 | 659.50 | 474.03 | |
| Total Expenses | 1,930.03 | 1,790.36 | 1,714.77 | 1,664.97 | 1,238.19 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 624.80 | 505.45 | 343.83 | 474.98 | 394.41 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 624.80 | 505.45 | 343.83 | 474.98 | 394.41 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 172.04 | 148.03 | 107.89 | 129.52 | 102.11 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | -39.49 | -4.87 | -5.14 | -1.79 | -4.18 | |
| Other Direct Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 132.55 | 143.16 | 102.75 | 124.69 | 97.93 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 492.25 | 362.29 | 241.08 | 350.29 | 296.48 | |
| Profit/Loss From Continuing Operations | 492.25 | 362.29 | 241.08 | 350.29 | 296.48 | |
| Profit/Loss For The Period | 492.25 | 362.29 | 241.08 | 350.29 | 296.48 | |
| Minority Interest | -5.11 | -4.56 | -2.23 | -5.46 | -4.86 | |
| Consolidated Profit/Loss After MI And Associates | 487.14 | 357.74 | 238.85 | 344.83 | 291.62 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 58.00 | 43.00 | 29.00 | 42.00 | 35.00 | |
| Diluted EPS (Rs.) | 58.00 | 43.00 | 29.00 | 42.00 | 35.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 199.91 | 199.48 | 99.43 | 115.71 | 99.11 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
12.03.2026
Dr Lal PathLab Standalone December 2025 Net Sales at Rs 632.10 crore, up 19.69% Y-o-Y
12.02.2026
05.02.2026
Dr Lal PathLab Consolidated December 2025 Net Sales at Rs 659.80 crore, up 10.57% Y-o-Y
03.02.2026
Dr Lal PathLab Standalone December 2025 Net Sales at Rs 632.10 crore, up 19.69% Y-o-Y
12.03.2026
Dr Lal PathLab Standalone December 2025 Net Sales at Rs 632.10 crore, up 19.69% Y-o-Y
05.02.2026
Dr Lal PathLab Consolidated December 2025 Net Sales at Rs 659.80 crore, up 10.57% Y-o-Y
03.02.2026
Dr Lal PathLab Standalone December 2025 Net Sales at Rs 632.10 crore, up 19.69% Y-o-Y
10.11.2025
Dr Lal PathLab Standalone September 2025 Net Sales at Rs 699.60 crore, up 19.82% Y-o-Y
06.10.2021
Dr. Lal PathLabs Q2 PAT seen up 28.4% YoY to Rs 112 cr: Prabhudas Lilladher
18.01.2021
Dr. Lal PathLabs Q3 PAT seen up 27.4% YoY to Rs. 54.1 cr: Prabhudas Lilladher
11.10.2019
Dr Lal Pathlabs Q2 PAT seen up 48.8% YoY to Rs. 84.8 cr: Kotak
15.07.2019
Dr Lal Pathlabs Q1 PAT seen up 17.6% YoY to Rs. 58.1 cr: Kotak
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth